STOCK TITAN
  1. Home
  2. News
  3. COEP

Coeptis Therapeutics Holdings Inc. - COEP STOCK NEWS

Welcome to our dedicated page for Coeptis Therapeutics Holdings news (Ticker: COEP), a resource for investors and traders seeking the latest updates and insights on Coeptis Therapeutics Holdings stock.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company focused on developing cell therapy platforms for patients with cancer, autoimmune, and infectious diseases. The company's product portfolio includes multi-antigen CAR T technology known as SNAP-CAR, CD38-GEAR-NK cell therapy technology, and CD38-Diagnostic in vitro diagnostic for CD38-related cancers. Coeptis has strategic partnerships with Deverra Therapeutics, VyGen-Bio, the University of Pittsburgh, and the Karolinska Institutet to advance its innovative therapies. With a strong emphasis on research and development, Coeptis aims to revolutionize treatment paradigms and improve patient outcomes across various therapeutic areas.

News

Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Rhea-AI Summary
Coeptis Therapeutics announces acceptance of abstract involving SNAP-CAR for presentation at SITC 2023, validating its potential in cancer therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa

Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. announces presentation at 2023 Cell & Gene Meeting on the Mesa. Dr. Delaney to discuss positive safety results for DVX201 in AML, MDS, and COVID-19 patients. Virtual attendance available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.31%
Tags
conferences
-
News

Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection

Rhea-AI Summary
Coeptis Therapeutics reports positive safety results for DVX201 cell therapy in Phase 1 trials for AML, MDS, and COVID-19 patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.08%
Tags
clinical trial covid-19
News

Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment

Rhea-AI Summary
Deverra Therapeutics receives grants totaling $3.5 million for CAR-NK and myeloid cell programs in cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.29%
Tags
none
-
News

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

Rhea-AI Summary
Coeptis Therapeutics has appointed Dr. Colleen Delaney as its Chief Scientific and Medical Officer after securing exclusive rights from Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs. Dr. Delaney brings over two decades of experience in oncology and stem cell transplant, with expertise in cell therapy product development. She will lead Coeptis in developing off-the-shelf cellular immunotherapies for cancer and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
management
-
News

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. has acquired key assets from Deverra Therapeutics Inc. to bolster its pipeline. The transaction includes two Phase 1 clinical stage assets for NK cell therapies in acute myeloid leukemia and respiratory infections. Coeptis also gains a scalable allogeneic cellular immunotherapy platform. The company paid $570,000 in cash and issued 4,000,000 shares of common stock to Deverra.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
none
News

Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.59%
Tags
none
-
News

Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.06%
Tags
none
News

Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.69%
Tags
none

FAQ

What is the current stock price of Coeptis Therapeutics Holdings (COEP)?

The current stock price of Coeptis Therapeutics Holdings (COEP) is $0.1415 as of December 20, 2024.

What is the market cap of Coeptis Therapeutics Holdings (COEP)?

The market cap of Coeptis Therapeutics Holdings (COEP) is approximately 5.6M.

What is Coeptis Therapeutics Holdings Inc focused on?

Coeptis is dedicated to developing cell therapy platforms for cancer, autoimmune, and infectious diseases.

What are the key products in Coeptis' portfolio?

The company's product portfolio includes SNAP-CAR multi-antigen CAR T technology, CD38-GEAR-NK cell therapy technology, and CD38-Diagnostic in vitro diagnostic.

Who are some of Coeptis' strategic partners?

Coeptis has strategic partnerships with Deverra Therapeutics, VyGen-Bio, the University of Pittsburgh, and the Karolinska Institutet.

What is Coeptis' goal in their research and development efforts?

Coeptis aims to revolutionize treatment paradigms and improve patient outcomes across various therapeutic areas.

Stock COEP logo
Coeptis Therapeutics Holdings Inc.

Nasdaq:COEP

COEP Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

COEP Stock Data

5.64M
31.46M
18.53%
4.28%
0.39%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WEXFORD